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Introduction 57
Bovine somatotropin (bST), with the majority isoform of 191-amino acid protein and a 58 molecular weight of 21802 Daltons (Table 1) , is produced and secreted by the anterior 59 pituitary gland. Through a complex network system, the somatotropic axis, this hormone 60 regulates several physiological processes involved in metabolism, growth and reproduction 61 [1] . It is well documented that the exogenous administration of bST redirects nutritional 62 partitioning towards milk synthesis in dairy cows, which is therefore translated into an 63 increase in milk production ranging from 10 going hormone debates between the EU and the USA, controversy has surrounded rMbST 73 since it became commercially available in 1994, with growing concern about the implications 74 of the administration of this synthetic protein on human and animal health and welfare. 75
Several adverse effects reported for treated animals include diminished fertility and an 76 increased occurrence of lameness and clinical mastitis [5, 6] , which requires additional 77 antibiotic treatments that may cause further food safety concern regarding antibiotic residues 78 in dairy and other food products. Extensive use of antibiotics in modern agricultural farming 79 has also been linked to the development and emergence of antibiotic resistance that is A c c e p t e d M a n u s c r i p t 5 administration of somatotropin raises the concentration of Insulin-like Growth Factor 1 (IGF-82 1) in milk [8] . Elevated circulating levels of IGF-1 have been associated with a higher risk of 83 developing several types of cancer [9, 10] . However, studies correlating the intake of milk 84 from rMbST-treated animals with human diseases are still lacking. 85
In order to control illegal administration of rMbST and to ensure high quality and safety of 86 milk and consumer protection, reliable analytical methodologies capable of unambiguous 87 identification of the synthetic methionyl growth hormone in milk are required. Current 88 analytical methods for determination of rMbST rely on instrumental technologies such as 89 HPLC-MS/MS [11] [12] [13] [14] . Despite the fact that chromatographic systems are highly sensitive 90 and specific, these techniques often limit their applications for rapid screening of a large 91 number of samples due to the requirement of extensive sample preparation time and 92 sophisticated instrumentation which is also laboratory-based. Immunoanalytical methods, in 93 particular Enzyme-Linked Immunosorbent Assays (ELISA), are widely used as rapid 94 screening tools for routine monitoring of food contaminants and residues, owing to their 95 simplicity, cost-effectiveness and capabilities of performing high-throughput analysis. Two 96 different immunoanalytical approaches have been adopted for the detection of rMbST. By the 97 direct strategy, the presence of the native and the recombinant isoforms is determined 98 simultaneously in biological fluids [15] [16] [17] , whereas the indirect approach is based on the 99 analysis of biomarkers of which their concentration is increased upon rMbST administration. 100 IGF-1 has been the traditional target measured for this purpose [8, [17] [18] [19] [20] . Methods based on 101 the detection of anti-rMbST immunoglobulins in treated cows have also been published [21, 102 22 ]. Nevertheless, the direct analysis of rMbST itself is highly preferable, in order to 103 circumvent problems associated with inter and intra-individual variation of biomarkers A c c e p t e d M a n u s c r i p t 6 To date, no specific immunoassays have been described for the detection of rMbST. The high 106 sequence homology displayed by the recombinant and the native somatotropins (methionine 107 in substitution of alanine at the N-terminus) has greatly hindered the successful production of 108 rMbST-selective antibodies. The strategy most often used entails the immunization with the 109 complete recombinant protein [21, [23] [24] [25] . Nevertheless, the antibodies produced following 110 this procedure have generally failed in their capacity to immunodiscriminate between bST 111 and rMbST, while a 2-fold increased affinity factor towards rMbST was described for the 112 mAb-based sandwich assay developed by Erhard et al [23] . Considering that only one amino 113 acid of difference at the N-terminus is encountered, the immunization with the whole protein 114 most likely leads to the production of antibodies directed towards shared epitopes in both 115 counterparts, bST and rMbST, therefore being unable to specifically recognize the latter. On 116 the other hand, a frequently accomplished practice for raising antibodies against proteins is 117 based on the use of immunizing synthetic peptide fragments which mimic concrete sequences 118 within the target [26-28]. The immunization with a synthetic peptide representing the 119 differential N-terminus of rMbST could a priori focus the immune response towards the 120 recognition of the characteristic epitope of the protein. Castigliego et al described for the first 121 time the production of a mAb by using a synthetic nine amino acid rMbST N-terminus-122 mimicking peptide coupled to KLH as immunogen [16] . Despite showing a 3-fold higher 123 affinity towards rMbST than to bST, complete immunodiscrimination was not yet possible by 124 using the developed immunoassays. As an alternative to monovalent peptides, multiple 125 antigen peptides (MAPs) or multimerized peptides, have been used as immunogens since 126 they were developed in 1988 [29] , especially in the area of vaccine development [30] [31] [32] . 127
MAPs have been shown to efficiently improve the immunogenicity of a particular antigen, 128 thus eliciting a stronger immune response, as a consequence of the presentation of multiple A c c e p t e d M a n u s c r i p t 7 immune response is generally mono-specific and more homogeneous [34] . The production of 131 pAbs targeted at vertebrate somatotropins using a synthetic MAP constituted by several 132 copies of an 18 amino acid highly conserved domain proximal to the C-terminus of the 133 protein has already been published [35] . To our knowledge this system has never been 134 applied before for the production of rMbST-specific antibodies. 135
In the present work several immunization strategies have been compared for the production 136 of anti-rMbST rabbit pAbs. The immunization with an octavalent synthetic rMbST N-137 terminus dipeptide-mimicking MAP, followed by affinity purification with a synthetic 138 rMbST N-terminus-mimicking linear peptide, resulted in the production of a pAb capable of 139 specifically differentiating between the recombinant and the native somatotropins in a 140 competitive ELISA format. 141 increasing to 50% in 5 min, then decreasing to initial conditions in 5 min and remaining at 215 10% A for 5 more minutes. A divert valve was used to let the sample pass into the instrument 216 from 4.5 to 9 min. The typical expected retention time was 6.7 and 6.9 min for the rMbST N-217 terminus peptide and the rMeST N-terminus peptide (used as internal standard), respectively. 218
Experimental
The MS instrument was a linear ion trap coupled to an orbitrap allowing high resolution 219 measurements (LTQ-Orbitrap TM , Thermo Electron, Bremen, Germany), fitted with an 220 electrospray ion source (ESI). The API interface was operated in positive ion mode. A sample 221 volume of 20 µL was loaded onto the column using the autosampler. A column heater was 222 used to ensure a stable column temperature of 30 °C. Mass spectrometric analyses were 223 performed in the following working conditions: capillary voltage was set at 42 V, source 224 voltage at 5 kV and capillary temperature at 300 °C. Nitrogen was used as sheath, auxiliary 225 and sweep gas at flow rates of 50, 10 and 10 (arbitrary unit), respectively. The linear ion trap with the exception of rMbST-KLH, for which 0.1 mg were used. Immunizations were 253 performed initially in intervals of 15 days, and then monthly after the third boost. A test 254 blood sample was obtained from every rabbit prior to immunization, and then 10 days after 255 each immunization from the 3 rd boost onward. Pre-immune and immune sera were obtained 256 by coagulation and centrifugation of the blood samples. Working solutions were prepared in a 257 1:1 mixture of EIA buffer and ethylene glycol, and they were stored at -20 °C. 258
Peptide-based affinity purification of the polyclonal antibody MU11 259
The pAb MU11 was purified by affinity chromatography using a peptide EP093536 column. By the immunization of rabbits with the three mentioned immunogens, 9 polyclonal 347 antibodies were obtained (Table 2) . 348
Preliminary antibody characterization 349
The capability of immunodiscrimination of the 9 available pAbs between the native and the 350 recombinant methionyl somatotropins was initially assessed by a checkerboard titration 351 procedure in the antigen-coated ELISA format using both proteins as coating antigens. As a 352 first approach, the crude sera were analyzed without any further purification. As shown in 353 Table 3 , all three immunogens gave rise to a positive immune response. All of the antibodies, 354 with only one exception (M10), recognized the native somatotropin and/or the recombinant 355 methionyl isoform to a different extent. Despite immunization with rMbST-KLH generated 356 the pAbs with the highest titers, these were unable to immunodiscriminate the recombinant 357 methionyl isoform, therefore displaying a very similar binding behavior towards both 358 somatotropins. From these results and those described in previous studies where the same 359 immunizing strategy was used [21, 23-25], it could be inferred that using the complete 360 recombinant protein as immunogen directs the immune response towards common antigenic 361 determinants within the recombinant and the native isoforms, with the rMbST N-terminus 362 being "masked". This remark is of special relevance in the case of pAbs, representing a 363 heterogeneous collection of antibodies with disparate profiles of selectivity, where the 364 rMbST-specific sub-population, if produced, would consequently be in the minority. Finally, 365 the immunogens consisting of rMbST N-terminus-mimicking synthetic peptides (both the 366 linear peptide and the MAP), afforded the most promising results, as three of the produced A c c e p t e d M a n u s c r i p t MU9 and MU11 for MF-MAP-SMCC-KLH. These antibodies were therefore selected for 369 further studies. 370
In order to reduce background-associated problems encountered with the raw sera, the three 371 pAbs were purified by protein A affinity chromatography. A representative set of data of the 372 response to rMbST and bST of the mentioned protein A purified antibodies by checker-board 373 titration in the antigen-coated ELISA is displayed in Figure 2 , including also one of the 374 generic pAbs (BC8) for comparative purposes. The highest rMbST/bST recognition ratio was 375 observed for pAb MU11, therefore highlighting the superior efficiency of the immunogen 376 based on the rMbST N-terminus-mimicking MAP coupled to KLH over the other strategies 377 used. Despite the fact that suitable amino acid number in MAPs is usually considered to be 378 comprised between 10 and 20 residues [35], the immunization with an rMbST N-terminus 379 dipeptide-mimicking MAP has been proven to be sufficiently immunogenic to induce the 380 production of anti-rMbST antibodies. 381
In conclusion, as previously reported by other authors regarding the production of antibodies 382 directed to other targets [33, 36] , the immunization with a MAP resulted in a stronger and/or 383 more specific response than that generated by a mimicking monovalent peptide or the 384 complete recombinant protein. According to the results herein presented, the rabbit pAb 385 MU11 was chosen for the development of an anti-rMbST immunoassay. 386
Competitive immunoassay based on the polyclonal antibody MU11 387
Those combinations of antibody dilution/coating antigen (rMbST) affording adequate signal 388 intensity (around 1 absorbance units), as determined by checker-board titration, were selected 389 to perform inhibition experiments using rMbST and bST as competitors. A preliminary 390 experiment was carried out to determine the assay conditions generating the highest A c c e p t e d M a n u s c r i p t 18 antibody and the competitor in combination with a short period of time for the competitive 393 step provided an improvement of the assay sensitivity (results not shown). Compensation of 394 signal loss due to the reduction of the immunoreactive step time was achieved using a signal 395 amplification system based on a biotinylated secondary antibody and HRP-labeled 396 streptavidin. As shown in Figure 3 , a specific response was displayed by the antibody MU11 397 towards rMbST, whereas no inhibition was observed when bST was used as competitor. All 398 of the evaluated combinations afforded very similar inhibition ratios for rMbST, with an 399 estimated IC 50 value comprised between 500 and 5000 μg L -1 . In order to improve the 400 antibody performance in terms of sensitivity, the pAb was subjected to a further purification 401 step using an rMbST N-terminus-mimicking synthetic peptide-based affinity procedure. The 402 affinity purification of antibodies produced against rMbST has been previously reported, 403
although in all of the described methods the complete recombinant protein was used with this 404 purpose [16, 17, 21, 25] . The competitive standard curves for rMbST and bST, as well as the 405 assay conditions and parameters obtained using the peptide-purified MU11 pAb in the most 406 sensitive coating antigen/antibody dilution combination are included in Figure 4 . By using 407 the peptide-purified fraction of the pAb MU11 the assay sensitivity was greatly improved, 408 being the resulting LOD for rMbST in buffer of 66 μg L -1 . This result indicates that antigen-409 based affinity purification is a convenient strategy not only to isolate the immunoglobulin 410 sub-populations directed to a ligand, but also to modulate the overall avidity of a pAb, and 411 thus the assay sensitivity, as those immunoglobulins with the lowest affinity towards the 412 target are removed during the washing step. Levels of rMbST/bST in fresh bovine milk after 413 administration of somatotropin slow release formulations have been reported to be below 5 A c c e p t e d M a n u s c r i p t 19 rMbST/bST content [14, 37] . In order to effectively monitor the presence of rMbST in milk 418 samples, further improvement of the MU11-based immunoassay herein presented is therefore 419 required, or alternatively, the production of additional receptors which display the specificity 420 to rMbST shown by pAb MU11, altogether with an increased affinity towards the target. As a 421 first approach, immunization with rMbST-mimicking MAPs bearing longer peptides will be 422 attempted, in order to determine the influence of the length of the displayed subunits in the 423 MAP on the avidity of the produced antibodies. whereas both recombinant proteins present the N-terminus methionine, two differences are 438 encountered (highlighted in bold). Given the decreased interaction observed for rMeST with 439 respect to rMbST, serine at position 6 and/or glycine at position 9 appear to be also required M a n u s c r i p t 20 rMbST N-terminus-mimicking linear peptide, would have contributed to the selection of 442 immunoglobulins which paratope would better fit an epitope containing these two amino 443 acids, therefore being specific for rMbST. 444
Conclusions 445
For decades the production of specific antibodies directed towards rMbST has not been 446 successfully accomplished as a consequence of an extremely minor difference (one amino 447 acid) encountered at the N-terminus of both proteins. In this paper, we report the generation 448 of a rabbit pAb displaying a high selectivity towards rMbST in a competitive antigen-coated 449 ELISA format. The immunogen employed for the production of the pAb consisted in an 450 rMbST N-terminus-mimicking synthetic MAP displaying the first two amino acids of rMbST 451 conjugated to the carrier protein KLH. Further purification of the antibody using an rMbST 452 N-terminus-mimicking synthetic linear peptide significantly improved the performance of the 453 antibody. Further work is currently ongoing in order to produce rMbST-specific monoclonal 454 and polyclonal antibodies to efficiently develop an immunoassay that meets the requirements 455 both in terms of specificity and sensitivity to be implemented for the routine screening of 456 rMbST in milk. 457 Table 3 . Summary of the preliminary characterization of the pAbs by antigen-coated ELISA. 532 
